Literature DB >> 10963297

Mithramycin represses MDR1 gene expression in vitro, modulating multidrug resistance.

M Tagashira1, T Kitagawa, S Isonishi, A Okamoto, K Ochiai, Y Ohtake.   

Abstract

The effect of an aureolic acid, mithramycin (MTM) on multidrug resistance (MDR) was investigated. At a concentration of 0.02--0.1 mg/ml (about 20--90 microM), MTM repressed MDR1 gene transcription of SBC-3/ADM, a MDR-phenotype subline derived from human small cell lung tumor. Under the same conditions, another aureolic acid, chromomycin A3, showed potent cytotoxicity. FACS analysis revealed that 5 microm MTM depleted the P-glycoprotein (Pgp) and lowered the efflux activity of SBC-3/ADM cells. Furthermore, MTM sensitized the cells against adriamycin. These results suggest that MTM would be a useful modulator of MDR induced by Pgp.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10963297     DOI： 10.1248/bpb.23.926

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN： 0918-6158            Impact factor:   2.233


  14 in total

1.  Deoxysugar transfer during chromomycin A3 biosynthesis in Streptomyces griseus subsp. griseus: new derivatives with antitumor activity.

Authors:  Nuria Menéndez; Mohammad Nur-e-Alam; Carsten Fischer; Alfredo F Braña; José A Salas; Jürgen Rohr; Carmen Méndez
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

2.  The loss of sarco/endoplasmic reticulum calcium transport ATPase 3 expression is an early event during the multistep process of colon carcinogenesis.

Authors:  Jean-Philippe Brouland; Pascal Gélébart; Tünde Kovàcs; Jocelyne Enouf; Johannes Grossmann; Béla Papp
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

3.  Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma.

Authors:  Janina Seznec; Björn Silkenstedt; Ulrike Naumann
Journal:  J Neurooncol       Date:  2010-06-17       Impact factor: 4.130

4.  Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity.

Authors:  Zhiliang Jia; Yong Gao; Liwei Wang; Qiang Li; Jun Zhang; Xiangdong Le; Daoyan Wei; James C Yao; David Z Chang; Suyun Huang; Keping Xie
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

5.  Semi-synthetic mithramycin SA derivatives with improved anticancer activity.

Authors:  Daniel Scott; Jhong-Min Chen; Younsoo Bae; Jürgen Rohr
Journal:  Chem Biol Drug Des       Date:  2013-04-04       Impact factor: 2.817

6.  Dimerization and DNA recognition rules of mithramycin and its analogues.

Authors:  Stevi Weidenbach; Caixia Hou; Jhong-Min Chen; Oleg V Tsodikov; Jürgen Rohr
Journal:  J Inorg Biochem       Date:  2015-12-18       Impact factor: 4.155

7.  A novel mithramycin analogue with high antitumor activity and less toxicity generated by combinatorial biosynthesis.

Authors:  Luz E Núñez; Stephen E Nybo; Javier González-Sabín; María Pérez; Nuria Menéndez; Alfredo F Braña; Khaled A Shaaban; Min He; Francisco Morís; José A Salas; Jürgen Rohr; Carmen Méndez
Journal:  J Med Chem       Date:  2012-06-07       Impact factor: 7.446

8.  Mithramycin encapsulated in polymeric micelles by microfluidic technology as novel therapeutic protocol for beta-thalassemia.

Authors:  Lorenzo Capretto; Stefania Mazzitelli; Eleonora Brognara; Ilaria Lampronti; Dario Carugo; Martyn Hill; Xunli Zhang; Roberto Gambari; Claudio Nastruzzi
Journal:  Int J Nanomedicine       Date:  2012-01-18

9.  Nanoparticulate formulations of mithramycin analogs for enhanced cytotoxicity.

Authors:  Daniel Scott; Jürgen Rohr; Younsoo Bae
Journal:  Int J Nanomedicine       Date:  2011-11-08

10.  The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF).

Authors:  V Duverger; A-M Murphy; D Sheehan; K England; T G Cotter; I Hayes; F J Murphy
Journal:  Br J Cancer       Date:  2004-05-17       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.